Brokerages Set Pacific Biosciences (PACB) PT at $6.27

Pacific Biosciences (NASDAQ:PACB) has received an average recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $6.27.

A number of analysts have weighed in on the company. BidaskClub raised Pacific Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 13th. Zacks Investment Research cut Pacific Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th.

Several large investors have recently made changes to their positions in the business. Teachers Advisors LLC lifted its position in shares of Pacific Biosciences by 2.2% in the fourth quarter. Teachers Advisors LLC now owns 1,029,585 shares of the biotechnology company’s stock worth $2,718,000 after buying an additional 21,835 shares during the last quarter. Mutual of America Capital Management LLC lifted its position in shares of Pacific Biosciences by 5.9% during the 4th quarter. Mutual of America Capital Management LLC now owns 510,472 shares of the biotechnology company’s stock worth $1,348,000 after purchasing an additional 28,384 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Pacific Biosciences by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 932,575 shares of the biotechnology company’s stock worth $2,461,000 after purchasing an additional 57,374 shares during the last quarter. Moloney Securities Asset Management LLC acquired a new position in shares of Pacific Biosciences during the 4th quarter worth about $154,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Pacific Biosciences by 23.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 459,558 shares of the biotechnology company’s stock worth $2,412,000 after purchasing an additional 86,415 shares during the last quarter. 58.93% of the stock is owned by institutional investors.

PACB traded down $0.04 during trading on Monday, reaching $2.55. 362,399 shares of the stock traded hands, compared to its average volume of 1,034,148. The stock has a market cap of $341.55, a price-to-earnings ratio of -2.93 and a beta of 1.61. Pacific Biosciences has a fifty-two week low of $2.02 and a fifty-two week high of $5.70. The company has a current ratio of 3.55, a quick ratio of 2.74 and a debt-to-equity ratio of 0.16.

Pacific Biosciences (NASDAQ:PACB) last released its quarterly earnings data on Thursday, February 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. The firm had revenue of $24.94 million during the quarter, compared to analysts’ expectations of $21.89 million. Pacific Biosciences had a negative return on equity of 98.98% and a negative net margin of 98.63%. The business’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.21) earnings per share. sell-side analysts forecast that Pacific Biosciences will post -0.63 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Pacific Biosciences (PACB) PT at $6.27” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3383025/brokerages-set-pacific-biosciences-pacb-pt-at-6-27.html.

Pacific Biosciences Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Receive News & Ratings for Pacific Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Markel Co.  Vice Chairman Steven A. Markel Sells 200 Shares
Markel Co. Vice Chairman Steven A. Markel Sells 200 Shares
Bottomline Technologies, Inc.  Director Peter Gibson Purchases 4,000 Shares
Bottomline Technologies, Inc. Director Peter Gibson Purchases 4,000 Shares
Old Dominion Freight Line  Director Leo H. Suggs Sells 800 Shares of Stock
Old Dominion Freight Line Director Leo H. Suggs Sells 800 Shares of Stock
Cara Therapeutics  SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Cara Therapeutics SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Analysts Set Nexeo Solutions  Price Target at $11.17
Analysts Set Nexeo Solutions Price Target at $11.17
Hologic, Inc.  Given Average Recommendation of “Hold” by Analysts
Hologic, Inc. Given Average Recommendation of “Hold” by Analysts


© 2006-2018 Ticker Report. Google+.